{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:34:32Z","timestamp":1790962472912,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Abbott Medical Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Safety of aspirin-free strategy immediately after percutaneous coronary intervention (PCI) for cardiovascular events in patients with diabetes was unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We conducted the prespecified subgroup analysis on diabetes in the STOPDAPT-3 trial, which randomly compared prasugrel (3.75\u00a0mg\/day) monotherapy (2984 patients) to dual antiplatelet therapy (DAPT) with prasugrel and aspirin (2982 patients) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding events (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. Of 5966 study patients, there were 2715 patients (45.5%) with diabetes. Patients with diabetes more often had chronic coronary syndrome, heart failure or cardiogenic shock, and comorbidities than those without. Patients with diabetes compared to those without had higher incidences of major bleeding and cardiovascular events. Regardless of diabetes, the effect of no-aspirin relative to DAPT was not different for the co-primary bleeding (diabetes: 5.05% vs. 5.47%; HR, 0.92; 95%CI, 0.66\u20131.28 and non-diabetes: 3.99% vs. 4.07%; HR, 0.98; 95%CI, 0.69\u20131.38; P for interaction\u00a0=\u00a00.81) and cardiovascular (diabetes: 5.54% vs. 5.15%; HR, 1.08; 95%CI, 0.78\u20131.49 and non-diabetes: 2.95% vs. 2.47%; HR, 1.20; 95%CI, 0.79\u20131.82; P for interaction\u00a0=\u00a00.70) endpoints. The incidences of subacute definite or probable stent thrombosis and any coronary revascularization were higher in the no-aspirin group than in the DAPT group regardless of diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The effects of an aspirin-free prasugrel monotherapy (3.75\u00a0mg\/day) relative to DAPT for major bleeding and cardiovascular events were not different regardless of diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae075","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:31:22Z","timestamp":1729744282000},"page":"34-44","source":"Crossref","is-referenced-by-count":6,"title":["An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial"],"prefix":"10.1093","volume":"11","author":[{"given":"Ko","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital , Kitakyushu 802-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-2317","authenticated-orcid":false,"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , Saga 849-0937 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9443-5915","authenticated-orcid":false,"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital , Hirakata 573-0153 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-739X","authenticated-orcid":false,"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Data Science, Hyogo Medical University , Nishinomiya 663-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-8877","authenticated-orcid":false,"given":"Yuki","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , Kyoto 606-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , Kyoto 606-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital , Kitakyushu 802-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital , Izunokuni 410-2211 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-0344","authenticated-orcid":false,"given":"Tsuyoshi","family":"Isawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sendai Kousei Hospital , Sendai 980-0873 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital , Hirakata 573-0153 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dokkyo Medical University Saitama Medical Center , Koshigaya 343-0845 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University Hospital , Isehara 259-1193 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tairo","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mie University Hospital , Tsu 514-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kaitani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Otsu Hospital , Otsu 520-0046 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sagamihara Kyodo Hospital , Sagamihara 252-5188 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ageo Central General Hospital , Ageo 362-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital , Kurashiki 710-0052 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Minamino Cardiovascular Hospital , Hachioji 192-0918 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Marianna University Hospital , Kawasaki 216-0015 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Uji-Tokushukai Medical Center , Uji 611-0041 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Miyabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Metropolitan Tama Medical Center , Fuchu 183-8524 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-980X","authenticated-orcid":false,"given":"Koh","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , Kyoto 606-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital , Hirakata 573-0153 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025020804505912400_bib1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2025020804505912400_bib2","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by Clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2025020804505912400_bib3","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"2025020804505912400_bib4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"eTicagrelor with or without Aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020804505912400_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor monotherapy vs Ticagrelor with Aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2025020804505912400_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"2025020804505912400_bib7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025020804505912400_bib8","first-page":"19","article-title":"Clopidogrel monotherapy after 1-month dual antiplatelet therapy in patients with diabetes undergoing percutaneous coronary intervention","volume":"16","author":"Yamamoto","year":"2023","journal-title":"JACC: Cardiovasc Interv"},{"key":"2025020804505912400_bib9","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025020804505912400_bib10","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2025020804505912400_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ J"},{"key":"2025020804505912400_bib12","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"2025020804505912400_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"eAn Aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"2025020804505912400_bib14","first-page":"763","article-title":"ePharmacodynamic effects of Vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study","volume":"4","author":"Franchi","year":"2019","journal-title":"JACC: Basic Trans Science"},{"key":"2025020804505912400_bib15","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of Diabetes: standards of medical care in Diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2025020804505912400_bib16","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2025020804505912400_bib17","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2025020804505912400_bib18","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"key":"2025020804505912400_bib19","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","article-title":"Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes Mellitus","volume":"142","author":"Capodanno","year":"2020","journal-title":"Circulation"},{"key":"2025020804505912400_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025020804505912400_bib21","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo","volume":"52","author":"Erlinge","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2025020804505912400_bib22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"2025020804505912400_bib23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"eGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in Myocardial infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"2025020804505912400_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMoa2216607","article-title":"Intravascular imaging-guided or angiography-guided complex PCI","volume":"388","author":"Lee","year":"2023","journal-title":"N Engl J Med"},{"key":"2025020804505912400_bib25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ J"},{"key":"2025020804505912400_bib26","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2025020804505912400_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4244\/EIJY14M06_09","article-title":"Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-Cypher registries","volume":"11","author":"Onuma","year":"2015","journal-title":"EuroIntervention"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae075\/60611783\/pvae075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/1\/34\/60611783\/pvae075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/1\/34\/60611783\/pvae075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T04:53:09Z","timestamp":1738990389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/1\/34\/7833553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae075","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,23]]}}}